Table 3.
Anti-CSF1/CSF1R monoclonal antibodies in clinical development
|
Code
|
Generic
|
Phase I Trial
|
Phase Ib Trial
|
|||
|
DLT
|
MTD
|
RP2D
|
Responder
|
ICI Partner
|
||
| CSF1R | ||||||
| AMG820[34,35] | Deafness | None | 1100 mg | None | Pembrolizumab (2 PRs in CRC, 1 PR in NSCLC) | |
| FPA008[36,37] | Cabiralizumab | None | None | 4 mg/kg | 4 PRs in TGCT | Nivolumab (4 PRs in PDAC) |
| LY3022855 (IMC-CS4)[38,39] | LVEF decrease, rhabdomyolysis + AKI, pancreatitis | None | 100 mg | None | Durvalumab | |
| RG7155[42] | Emactuzumab | None | None | 1000 mg | 2 CRs + 22 PRs in TGCT | Avelumab |
| SNDX6532[45,46] | Axatilimab | None | None | 6 mg/kg | None | Durvalumab |
| CSF1 | ||||||
| MCS110[47] | Lacnotuzumab | None | None | None | Spartalizumab (1 PR in PDAC) | |
| PD0360324 | Avelumab | |||||
AKI: acute kidney injury; CSF1: colony-stimulating factor 1; CSF1R: colony-stimulating factor 1 receptor; CR: complete response; CRC: colorectal cancer; DLT: dose-limiting toxicity; ICI: immune checkpoint inhibitor; LVEF: left ventricular ejection fraction; MTD: maximum tolerated dose; PDAC: pancreatic ductal adenocarcinoma; PR: partial response; RP2D: recommended phase II dose; NSCLC: non–small cell lung cancer; TGCT: tenosynovial giant cell tumor